Selegiline is a
monoamine oxidase inhibitor (MAOI) prescribed as an adjunct treatment for
Parkinson's disease and major depressive disorder. By
irreversibly blocking monoamine oxidase enzymes, it elevates the levels of
neurotransmitters like dopamine in the brain.
